Conference dates: January 25-29, 2025
Booth: 2252
Location: San Diego, CA
Poster 1 Title: Massively Parallel SPR-Based Fragment Screening of Kinase Arrays
Presenter: Anthony Giannetti, PhD, Associate Director, Applications, Carterra
Abstract: Kinases provide a wealth of opportunities for addressing human disease, but their presence in so many critical cellular functions presents challenges for developing drugs with the proper selectivity profiles for maximal therapeutic, and minimal toxic, effect. Direct label-free approaches, such as SPR, can complement activity assays by providing the intrinsic affinity, while observing the real-time kinetics, of interactions. In this poster, we highlight the power of combining an extensive panel of ready-made biotinylated kinases with HT-SPR to generate a wealth of compound binding information that can augment the drug discovery process with broader selectivity profiling in less time for less cost. Here we highlight the power of combining an extensive panel of ready-made biotinylated kinases with HT-SPR to generate a wealth of compound binding information. In three days over 125,000 interactions were measured between a panel of kinases and the Maybridge 1000 fragment library. We also profiled a kinase-focused small molecule library and obtained more than 80,000 binding interactions in a three-day instrument run. Detailed kinetics were then subsequently obtained for hits of interest. Beyond simple yes/no reporting, this approach allows for nuanced kinetic profiling for up to hundreds of binding events in parallel, thereby enabling thoughtful discovery of safe and efficacious drug candidates.
Poster 2 Title: Increasing DNA Encoded Library Screening Resolution Using HT-SPR
Presenter: Anthony Giannetti, PhD, Associate Director, Applications, Carterra
Abstract: DNA encoded library (DEL) technology has permitted substantial leaps in compound screening by enabling a more facile way to interrogate libraries and develop lead compounds. While a huge benefit to DEL technology is its reduction in the sheer number and tracking of discrete compounds through the screening process, it does come with a limitation in binding properties that can be gleaned for potential hits. In practice, from an initial screen numbering millions, the resulting thousands of hits are then reduced to around 50 compounds carried forward into downstream assays without any detailed characterization of their binding properties. These fundamental binding properties include kinetics as well as the target binding site. To address this resolution gap in DEL screening, demonstrated here is a technique to further characterize hits with improved resolution using high-throughput surface plasmon resonance (HT-SPR). HT-SPR characterizes the full kinetic profile for both weak and strong binders. Assay resolution can be further increased by inclusion of high-homology family members, truncated or mutated forms, binding partner disruption, etc., yielding a richer profile of lead candidates. With a screening capacity of thousands per week, HT-SPR affords a high-resolution technique that matches the throughput needs in this phase of discovery between the full library and a handful of leads. Additionally, this approach can work with any moiety having DNA attachment, including screening for targeted protein degraders (TPDs) and macrocycles.
Title: Massively Parallel SPR-Based Fragment Screening on Ligand Arrays
Presenter: Anthony Giannetti, PhD, Associate Director, Applications, Carterra
Date and Time: Monday, January 27 1:00 PM – 1:20 PM PST
Location: Solutions Spotlight Theater (Booth 2907)
Abstract: The era of proteomics and big data has paved the way for efficient utilization of higher-throughput and more expansive experimental characterization of biomolecular interactions. Drug discovery increasingly seeks to understand the interactions of hit- and lead-like molecules in context of the greater biological milieu in which pharmacological effects are sought. In practice lead-generation methodologies are constrained to screen one or a few targets at a time and enable hit-to-lead activities with a limited set of off-target/mutant paneling in-house, or through CROs. We propose that ligand-array biosensors can allow for testing interactions of compounds against up to hundreds of proteins at a time allowing for broad paneling using very little reagent and generating very precise differences between on/off targets, mutants, homologs, post-translational modifications, etc. SPR -based direct-binding assays do not require counter-screens for assay interference further speeding data interpretation. In one case a screen of the Maybridge 1000 fragment library against a panel of off-the-shelf biotinylated kinases resulted in ~125,000 fragment/protein interactions collected in 3 days. Another screen of 96 unique proteins against an ~3,500 compound library resulted in ~320,000 interactions in 11 days. Datasets of this type allow for the simultaneous assessment of selectivity, specificity, and ligandability. Use of these approaches through hit-to-lead activities will provide broader information to enable medicinal chemistry, pathway profiling, and earlier indications of off-target engagement.